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Background. There is high evidence for secondary
prevention of fractures, including hip fracture, with
alendronate treatment, but alendronate’s efficacy
to prevent hip fractures in the oldest-old (≥80 years
old), the population with the highest fracture risk,
has not been studied.
Objective. To investigate whether alendronate treat-
ment amongst the oldest-old with prior fracture
was related to decreased hip fracture rate and
sustained safety.
Methods. Using a national database of men and
women undergoing a fall risk assessment at a
Swedish healthcare facility, we identified 90 795
patients who were 80 years or older and had a
prior fracture. Propensity score matching (four to
one) was then used to identify 7844 controls to
1961 alendronate-treated patients. The risk of
incident hip fracture was investigated with Cox
models and the interaction between age and treat-
ment was investigated using an interaction term.
Results. The case and control groups were well
balanced in regard to age, sex, anthropometrics
and comorbidity. Alendronate treatment was asso-
ciated with a decreased risk of hip fracture in crude
(hazard ratio (HR) 0.62 (0.49–0.79), P < 0.001) and
multivariable models (HR 0.66 (0.51–0.86),
P < 0.01). Alendronate was related to reduced mor-
tality risk (HR 0.88 (0.82–0.95) but increased risk of
mild upper gastrointestinal symptoms (UGI) (HR
1.58 (1.12–2.24). The alendronate association did
not change with age for hip fractures or mild UGI.
Conclusion. In old patients with prior fracture, alen-
dronate treatment reduces the risk of hip fracture
with sustained safety, indicating that this treat-
ment should be considered in these high-risk
patients.
Keywords: alendronate, efficiency, elderly, fracture,
osteoporosis, treatment.
Introduction
In the United States alone, the population of
oldest-old (over 80 years of age) is expected to
increase from 11.7 million in 2012 to more
than 20 million in 2030 [1]. As the risk to
fracture increases exponentially with age [2],
the number of fractures is expected to increase
dramatically as a consequence. At the age of
50, the risk of sustaining a fragility fracture
(low energy trauma fracture) during the
remaining lifetime is 50% for women and 20%
for men [2]. Already today, patients with
fragility fractures require more in-hospital days
than breast and prostate cancer combined, a
figure exceeded only by those with stroke [3].
The increase in fracture rates will result in
enormous health care cost; already the yearly
fracture-related cost of osteoporosis in the
United States is estimated to $17 billion [4].
Hip fracture is the most severe fracture and
associated with increased morbidity and mor-
tality [5]. Between 40% and 60% of hip frac-
ture, survivors are not likely to recover their
546 ª 2017 The Authors. Journal of Internal Medicine published by John Wiley & Sons Ltd on behalf of Association for Publication of The Journal of Internal Medicine.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited and
is not used for commercial purposes.
Original Article
prefracture level of mobility [6], and the one-
year mortality is increased by 8–36% [7, 8].
There is strong evidence for secondary fracture
prevention with the bisphosphonate alendronate, a
treatment that results in a 40% relative risk
reduction (RRR) of hip fractures in post-
menopausal women [9]. However, as older patients
often suffer from multiple comorbidities preventing
the participation in clinical trials, none of the large
randomized trials (RCTs) included a significant
proportion of patients above the age of 80 years
[10]. An RCT investigating the effect of risedronate
on old women (n = 3886, aged 80–89) found no
clear hip fracture risk reduction [11]. However, that
study included women with one nonskeletal risk
factor for hip fracture or low BMD, whereas a
previous fracture was not required. Thus, there is
insufficient evidence regarding the effectiveness
and safety of oral bisphosphonate treatment
amongst the oldest-old.
The purpose of this study was to investigate
whether alendronate (which accounts for 93% of
all oral bisphosphonate use in Sweden [12]) pre-
scribed to older patients (≥80 years) with prior
fracture was related to a reduced risk of hip
fracture and sustained safety in a large cohort of
older men and women.
Materials and methods
Study design
The risk of hip fracture and expected adverse
events in older alendronate users and nonu-
sers was investigated in a prospective observa-
tional register-based study, using four to one
propensity score matching and multivariable
Cox models.
Study population
The ‘Fractures and fall injuries in the elderly
cohort’ (FRAILCO, [13]) is a national cohort based
on information from several Swedish national
registers, linked in order to study associations
regarding fractures, fall injuries, morbidity, mor-
tality and medications. Patients were initially
selected from the Senior Alert register, consisting
of men and women ≥65 years, who underwent a fall
risk assessment in connection to a visit to a
healthcare facility in Sweden between 2008 and
2014 [14]. All patients were included in the regis-
ter, without exclusion criteria. Senior Alert was
originally designed to follow and support improve-
ments in preventive care for older adults and
encompasses more than 90% of all municipalities
and counties throughout Sweden [14]. In 2014, it
included approximately 22% of the Swedish popu-
lation over 65 years of age [15].
After excluding patients with probable registry
errors as well as immigrants with insufficient
background data, patients aged 80 years or older
were selected. In order to emulate a secondary
prevention setting, only patients with a prior frac-
ture (index fracture) were included in the present
study. Patients with severe kidney failure (N184-
N185), that is not eligible for alendronate treat-
ment, were excluded (Fig. 1).
Ascertainment of alendronate treatment
Medication data were collected from the Drug
Dispensation Register (2005–2014). Only patients
being treatment na€ıve at the time of the index
fracture were included in the analysis either as
case or control. Patients starting alendronate
treatment after fracture were included as cases
and compared to patients who never received any
osteoporosis treatment after index fracture (con-
trols). All patients with other known osteoporotic
treatments (risedronate, zoledronic acid, deno-
sumab, testosterone, systemic oestrogens, stron-
tium ranelate, PTH-analogues and selective
oestrogen receptor modulators) before the risk
assessment were excluded from the analyses.
Alendronate patients with <3 months of treat-
ment or not currently treated (last dispensation
expected to be consumed but not renewed) were
also excluded. Currently treated was here defined
as having access to alendronate for at least three
months immediately before the risk assessment.
In order to balance the groups, controls with
<3 months between index fracture and risk
assessment were excluded. Thus, the resulting
alendronate variable represents use in the inter-
val between index fracture and risk assessment
and ongoing (current) at the time of the risk
assessment (Figs 1 and 2). Apart from the
dichotomous alendronate variable, others were
defined: alendronate treatment time was mea-
sured from the date of the first prescription after
the index fracture to the date when the last
prescription was used, truncated at the fall risk
assessment date (time zero). Medication posses-
sion ratio (MPR) was calculated as the sum of the
defined daily doses during the treatment time,
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divided by the treatment time resulting in a value
between 0 and 1. Concomitant medication was
accounted for if a retrieved prescription was
expected to be used within 90 days before base-
line and if there were at least two retrieved
prescriptions registered.
Fig. 1 Study population. (*) Accepted values after exclusion of top and bottom 1& of weight, height and BMI. Weight: 30-
176 kg; Height: 114-197 cm; BMI: 12.23–73.05 kg m2.
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Definition of fracture
Fracture information was collected from the
National Patient Register. All nonmalignant
fracture diagnoses in ICD-10 regardless of type
of trauma were included, apart from head
fractures (Table S1). If a fracture diagnosis on
the same skeletal site (ICD-10 two digits) was
repeated within five months, it was discarded as
it most likely was a revisit and not a new
fracture.
Ascertainment of hip fracture
The main outcome, hip fracture, was defined as a
fractured femoral head, neck, trochanter or sub-
trochanteric part of femur, in combination with a
code for surgical procedure (Table S2). Identifica-
tion of hip fracture using this procedure has high
accuracy [16]. Time to hip fracture was calcu-
lated from the time of the risk assessment to the
actual hip fracture, and censored for death (from
the Cause of Death Register), emigration (from
Statistics Sweden) and end of study period (31
December 2014).
Ascertainment of other outcomes
Other outcomes included major osteoporotic frac-
tures, any fracture (Tables S1 and S2), as well as
death. Dyspepsia, acid reflux and esophagitis were
combined from the National Patient Register to
analyse mild upper gastrointestinal (UGI) symp-
toms as a possible adverse outcome during follow-
up after risk assessment. Also, peptic ulcer, drug-
induced osteonecrosis and femoral shaft fractures
were analysed (Table S3). Time to mild UGI symp-
toms and peptic ulcer, respectively, were also
censored for death, emigration and end of study
period. Information regarding cause of death was
retrieved from the National Causes of Death Regis-
ter.
Assessment of morbidity and covariates
All data regarding prior illnesses before risk
assessment were collected from the National
Patient Register (2001–2014 for outpatient visits
and 1987–2014 for admitted patients). The register
collects information from hospitals but not from
primary care clinics. Clinical risk factors for
Fig. 2 Method overview.
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fracture, including rheumatoid arthritis, alcohol-
related diseases, previous glucocorticoid treatment
(≥5 mg per day for more than 3 months) as well
as diseases related to secondary osteoporosis
(insulin-dependent diabetes, hyperthyroidism,
hypogonadism, malnutrition, osteogenesis imper-
fecta or chronic liver disease), were accounted for.
Prevalent calcium and vitamin D treatment was
defined as a treatment length exceeding 3 months
occurring during the last 2 years prior to the risk
assessment. Charlson comorbidity index was used
to summarize and quantify comorbidity [17].
Covariate definitions are presented in Tables S2,
S4–S9. Characterization of mobility status, general
condition, food and liquid intake at the time of risk
assessment was performed using questions from
the validated RAPS or Norton scales [18]. Weight
and height were measured at the time of the risk
assessment and collected from Senior Alert.
Statistical analyses
Nontreated patients were matched through a four
to one propensity score matching according to age,
sex, weight, height, rheumatoid arthritis, alcohol-
related diseases, previous glucocorticoid treat-
ment, the individual diseases included in both
secondary osteoporosis definition (Table 1) and
Charlson comorbidity index as well as time since
index fracture, previous vertebral fracture, previ-
ous hip fracture, number of previous fractures,
previous fall injury and osteoporosis diagnosis
(M80-M81) [19, 20]. Differences between the
matched controls and the treated patients were
investigated using Fisher’s exact test on categorical
variables, chi-square test if multiple categories and
with t-tests on continuous variables. To investigate
the association between alendronate treatment
and fracture risk, we used a Cox proportional
hazards model starting at the date of the risk
assessment, adjusted for age, sex, weight and
height, and previous medication (glucocorticoids
and calcium/vitamin D), secondary osteoporosis,
rheumatoid arthritis, alcohol-related diseases,
Charlson comorbidity index, time since fracture,
previous vertebral fracture, previous hip fracture,
previous hip replacement, number of previous
fractures, previous fall injury and osteoporosis
diagnosis (multivariable adjustment). In contrast
to logistic regression, the Cox regression model
uses the length of each individual’s follow-up
period (Fig. 2). The follow-up time to fracture was
censored for death, emigration or end of study
period. Cox proportional hazard analyses were
repeated for all investigated alendronate treatment
variables: binary alendronate treatment variable
(yes/no), treatment length or medication posses-
sion ratio. To investigate whether the alendronate
association changed with age, an interaction term
between age and alendronate treatment was used
in the Cox model. To analyse whether the associ-
ation between alendronate and hip fracture was
dependent on prevalence of previous fall injury, an
interaction term between alendronate (yes/no) and
prevalent fall injury was constructed and tested in
the multivariable Cox model. When analysing the
other outcomes (mild UGI symptoms, peptic ulcers
or shaft fractures), adjustments were made for age,
sex, weight, height Charlson comorbidity index and
previous UGI symptoms, peptic ulcers or femoral
shaft fracture, respectively. When analysing death
as outcome, adjustment was made for age, sex,
weight, height and Charlson comorbidity index.
Statistical analyses were performed with the use of
IBM SPSS software, version 22, and the propen-
sity score matching was performed using R 3.3.2.
To address the issue of potential persistence bias
and the possible healthy adherer effect [21], we
analysed the persistence of the commonly used
drug acetylsalicylic acid and compared current
alendronate users with their matched untreated
controls. A P-value <0.05 was considered signifi-
cant. The Cox assumption of proportional hazards
was tested for all outcomes using a time-dependent
Cox model with a linear interaction term between
time and alendronate.
Results
The present study included a total of 9805 patients
of which 1961 had current alendronate treatment
at the time of the risk assessment and 7844
matched controls that never had had any osteo-
porosis medication (Table 1). The accumulated
follow-up time or time at risk was 14 800 years,
of which 3135 years in the treated group and 11
666 years in the untreated group. The mean time
at risk was significantly longer in the treated group
compared to the untreated (Table 2). All patients in
the treated group were currently being treated and
had a mean previous treatment time of 3.5 years,
during which the mean medication possession
ration was 91%. The primary inclusion sites were
hospital wards (46%) or nursing homes (38%), with
the remaining of the patients included at residen-
tial home care (8.6%), health centres (4.5%) and
rehabilitation units (3.1%). In the total cohort, 89%
of the patients were characterized to be in good or
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Table 1 Baseline characteristics
Description No alendronate Alendronate P-value
Number of patients 7844 1961
Female sex – no. (%) 6871 (87.6) 1719 (87.7) 0.97
Age, years – mean (SD) 85.7 (4.4) 85.7 (3.9) 0.63
Weight, kg – mean (SD) 62.1 (13.9) 62.3 (13.0) 0.52
Height, cm – mean (SD) 160.8 (8.4) 160.8 (8.1) 0.85
Alcohol-related diseases – no. (%) 32 (0.4) 7 (0.4) 0.84
Rheumatoid arthritis – no. (%) 367 (4.7) 110 (5.6) 0.09
Previous ‘intense’ glucocorticoid – no. (%) 1909 (24.3) 515 (26.3) 0.08
Time since fracture, years – mean (SD) 5.7 (4.2) 5.9 (3.6) 0.20
Previous fall injury – no. (%) 5569 (71.0) 1366 (69.7) 0.24
Previous hip fracture – no. (%) 1806 (23.0) 436 (22.2) 0.47
Previous hip replacement – no. (%) 1271 (16.2) 331 (16.9) 0.47
Previous vertebral fracture – no. (%) 1949 (24.8) 506 (25.8) 0.38
Number of previous fractures – no. (%) 0.28*
1 5728 (73.0) 1423 (72.6)
2 1426 (18.2) 395 (20.1)
≥3 690 (8.8) 143 (7.3)
Osteoporosis – no. (%) 2125 (27.1) 632 (32.2) <0.001
Secondary osteoporosis – no. (%) 337 (4.3) 94 (4.8) 0.36
Insulin-dependent diabetes – no. (%) 215 (2.7) 55 (2.8) 0.88
Hyperthyroidism – no. (%) 165 (2.1) 46 (2.3) 0.49
Hypogonadism – no. (%) 0 (0) 0 (0) –
Malnutrition – no. (%) 33 (0.4) 8 (0.4) 1.00
Osteogenesis imperfecta – no. (%) 0 (0) 0 (0) –
Chronic liver disease – no. (%) 37 (0.5) 1 (0.1) 0.86
Charlson morbidity index 0.67*
0 2842 (36.2) 722 (36.8)
1–2 2739 (34.9) 656 (33.5)
≥3 2263 (28.9) 583 (29.7)
Charlson morbidity components:
Ischaemic heart diseases – no. (%) 1596 (20.3) 419 (21.4) 0.32
Congestive heart failure – no. (%) 1413 (18.0) 366 (18.7) 0.51
Cerebrovascular diseases – no. (%) 1530 (19.5) 376 (19.2) 0.75
Diseases of arterioles and capillaries – no. (%) 666 (8.5) 170 (8.7) 0.79
Diabetes – no. (%) 829 (10.6) 211 (10.8) 0.81
Dementia – no. (%) 840 (10.7) 202 (10.3) 0.62
Chronic pulmonary disease – no. (%) 935 (11.9) 245 (12.5) 0.49
Chronic liver disease – no. (%) 37 (0.5) 10 (0.5) 0.86
Renal failure, mild – no. (%) 256 (3.3) 64 (3.3) 1.00
Renal failure, moderate – no. (%) 33 (0.4) 11 (0.6) 0.45
Peptic ulcer disease – no. (%) 287 (3.7) 73 (3.7) 0.89
Hemiplegia – no. (%) 150 (1.9) 33 (1.7) 0.58
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fairly good general condition, 74% ate three quar-
ters of a portion or more and 85% drank 700 mL or
more each day (Table S10). At baseline, 40.7% of
the patients had full mobility, 34.8% had slightly
limited mobility, 13.5% had very limited mobility,
0.8% were immobile, and 10.2% had missing data.
Patients immigrating to Sweden 2004 or earlier
amounted to 8.5% (836).
Apart from osteoporosis being more common
amongst the treated patients, there were no signif-
icant differences in prevalent diseases or risk
factors for fracture, between the treated and
untreated patients (Table 1). There were no signif-
icant differences between groups in terms of gen-
eral condition or food portion sizes, whilst reduced
liquid intake was significantly more common in the
untreated group (Table S10). At baseline, alen-
dronate-treated patients more frequently used
diuretics, statins, calcium channel blockers, angio-
tensin-converting enzyme inhibitors and opioids
but less frequently used benzodiazepines than
patients not treated with alendronate (Table S11).
Calcium and vitamin D supplementation, normally
prescribed together with alendronate, was used by
85% in the alendronate group and by 30% in the
untreated group.
Hip fracture incidence in the alendronate-treated
patients was significantly lower than in the
untreated patients, in both percentage and per
100 000 person-years (Table 2a). In a crude Cox
model, alendronate treatment was associated with
a 38% reduced risk of hip fracture. The association
was somewhat attenuated, but remained highly
significant in a multivariable Cox models
(Tables 2a and 3; Fig. 3). The three-year absolute
risk reduction (ARR), based on the multivariable
Cox models, was estimated to 3.9%, corresponding
to number needed to treat (NNT) of 26. These
associations were maintained for both men and
women analysed separately (Table S11). The inter-
action term of age and alendronate was not asso-
ciated with hip fracture risk in a multivariable Cox
model (P = 0.49), indicating no age-dependent
alendronate association. In the whole cohort,
6935 patients had suffered a previous fall injury.
In the multivariable Cox model, alendronate was
associated with hip fracture in these patients
(hazard ratio (HR) 0.64 (0.47-0.87)), but the asso-
ciation was not significant in patients without a
prevalent fall injury (n = 2870, HR 0.72 (0.45-
1.18). There was no significant interaction between
alendronate use (yes/no) and previous fall injury
(P = 0.85 for the interaction term).
Repeating the multivariable-adjusted Cox model
with alendronate treatment length as a predictor
instead of alendronate yes/no revealed that treat-
ment length was associated with a 9% reduced risk
of hip fracture per year of treatment. Using the
same Cox model with medication possession ratio
(MPR) instead of alendronate treatment length, we
found that alendronate MPR was associated with a
4% reduced risk of hip fracture per 10 per cent
improvement of MPR (Table 2a).
Alendronate treatment was also associated with
significant risk reductions in major osteoporotic
and any fracture, in both crude and multivariable
Cox models (Table 2a).
The multivariable-adjusted cox models used to
study the associations between alendronate and
hip fracture were essentially unaffected when also
including adjustments for (i) general condition,
portion size and liquid intake (HR for alendronate
treatment 0.66 (0.51–0.86); (ii) inclusion site (HR
0.67 (0.52–0.87)); and (iii) mobility status HR 0.65
(0.49–0.85).
The mortality rate in the alendronate-treated group
was significantly lower both in percentage and per
100 000 person-years (Table 2b). Using a multi-
variable Cox model, alendronate treatment was
associated with a 12% reduced mortality risk
(Table 2b). Analysis on causes of deaths revealed a
nonsignificant trend that hip fracture-related
deaths were reduced with alendronate, whilst there
were no significant differences in deaths related to
Table 1 (Continued )
Description No alendronate Alendronate P-value
Tumour without metastasis (<5 years) – no. (%) 1683 (21.5) 425 (21.7) 0.83
Metastatic solid tumour – no. (%) 176 (2.2) 45 (2.3) 0.87
Lymphoma or leukaemia – no. (%) 138 (1.8) 32 (1.6) 0.77
*v2 test.
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Table 2 (a) Fracture risk and alendronate treatment. (b) Other outcomes and alendronate treatment
Description No alendronate Alendronate P-value
(a)
Patients – no. 7844 1961
Time at risk, days – mean (SD) 543 (418) 584 (436) <0.001
Hip fracture
No. (%) 484 (6.2) 81 (4.1) <0.01
Per 100 000 person-years 4149 2584 <0.001
Time to fracture, days – mean (SD) 366 (326) 426 (317) 0.12
Alendronate treatment (yes/no) HR (95% CI)
Crude 0.62 (0.49–0.79) <0.001
Adjusted for age, sex, weight, height 0.62 (0.49–0.79) <0.001
Multivariable adjustmenta 0.66 (0.51–0.86) <0.01
3 years ARR – multivariable adjustmenta 3.9%
3 years NNT – multivariable adjustmenta 26
Alendronate treatment time (years)
HR per year (95% CI) – multivariable adjustmenta 0.91 (0.85–0.97) <0.01
Alendronate medication possession ratio (MPR)
HR per 10% MRP (95% CI) – multivariable adjustmenta 0.96 (0.93–0.98) <0.01
Major osteoporotic fractures
No. (%) 641 (8.2) 117 (6.0) <0.01
Per 100 000 person-years 5495 3733 <0.001
Time to fracture, days – mean (SD) 353 (318) 389 (333) 0.27
Alendronate treatment (yes/no) HR (95% CI)
Crude 0.68 (0.56–0.83) <0.001
Adjusted for age, sex, weight, height 0.68 (0.56–0.83) <0.001
Multivariable adjustmenta 0.70 (0.56–0.87) <0.01
3 years ARR – multivariable adjustmenta 4.3%
3 years NNT – multivariable adjustmenta 23
Alendronate treatment time (years)
HR per year (95% CI) – multivariable adjustmenta 0.93 (0.88–0.98) <0.01
Alendronate medication possession ratio (MPR)
HR per 10% MRP (95% CI) – multivariable adjustmenta 0.96 (0.94–0.99) <0.01
Any fracture
No. (%) 1020 (13.0) 214 (10.9) 0.01
Per 100 000 person-years 8743 6827 <0.01
Time to fracture, days – mean (SD) 339 (313) 386 (338) 0.05
Alendronate treatment (yes/no) HR (95% CI)
Crude 0.78 (0.67–0.90) <0.01
Adjusted for age, sex, weight, height 0.78 (0.67–0.90) <0.01
Multivariable adjustmenta 0.77 (0.66–0.91) <0.01
3 years ARR – multivariable adjustmenta 5.0%
3 years NNT – multivariable adjustmenta 20
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Table 2 (Continued )
Description No alendronate Alendronate P-value
Alendronate treatment time (years)
HR per year (95% CI) – multivariable adjustmenta 0.97 (0.93–1.00) 0.07
Alendronate medication possession ratio (MPR)
HR per 10% MRP (95% CI) – multivariable adjustmenta 0.97 (0.96–0.99) <0.01
(b)
Deaths
No. (%) 3422 (43.6) 792 (40.4) 0.01
Per 100 000 person-years 29 333 25 267 <0.001
Time to death, days – mean (SD) 396 (355) 416 (362) 0.16
Alendronate treatment (yes/no) HR (95% CI)
Crude 0.87 (0.80–0.94) <0.001
Adjusted for age, sex, weight, height 0.89 (0.82–0.96) <0.01
Adjusted for age, sex, weight, height and Charlson comorbidity
index
0.88 (0.82–0.95) <0.01
3 years ARR – adjusted for age, sex, weight, height and Charlson
comorbidity index
5.2%
3 years NNT – adjusted for age, sex, weight, height and Charlson
comorbidity index
19
Mild upper gastrointestinal symptoms (UGI)
No. (%) 110 (1.4) 45 (2.3) <0.01
Per 100 000 person-years 943 1436 0.02
Time to UGI, days – mean (SD) 297 (297) 333 (293) 0.49
Alendronate treatment (yes/no) HR (95% CI)
Crude 1.57 (1.11–2.21) 0.01
Adjusted for age, sex, weight, height 1.57 (1.11–2.22) 0.01
Adjusted for age, sex, weight, height, Charlson comorbidity index
and previous UGI
1.58 (1.12–2.24) 0.01
3 years ARR – adjusted for age, sex, weight, height, Charlson
comorbidity index and previous UGI
1.1%
3 years NNH – adjusted for age, sex, weight, height, Charlson
comorbidity index and previous UGI
91
Peptic ulcers
No. (%) 82 (1) 23 (1.2) 0.62
Per 100 000 person-years 703 734 0.86
Time to peptic ulcers, days – mean (SD) 242 (277) 401 (365) 0.03
Alendronate treatment (yes/no) HR (95% CI)
Crude 1.08 (0.68–1.71) 0.76
Adjusted for age, sex, weight, height 1.08 (0.68–1.71) 0.76
Adjusted for age, sex, weight, height, Charlson comorbidity index
and previous peptic ulcer
1.06 (0.67–1.69) 0.80
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cancer, stroke or acute myocardial infarction
between treated anduntreated patients (Table S12).
The incidence of mild UGI symptoms (dyspepsia,
reflux or esophagitis) was significantly higher
amongst the alendronate-treated compared to the
untreated group (Table 2b). In a multivariable Cox
model, alendronate treatment was associated with
58% increased risk of mild UGI symptoms. Using
the interaction term in the adjusted Cox model
revealed no significant age-dependent alendronate
association with risk of UGI (P = 0.81). The three-
year absolute risk increase was 1.1% correspond-
ing to a number needed to harm (NNH) of 91.
Treatment was not associated with an increased
risk of incident peptic ulcers in a multivariable Cox
model (Table 2b).
Drug-induced osteonecrosis was rare with only one
case in the treated group. Atypical femur fractures
(AFFs)cannotbespecifically identifiedusingregister
data, but the frequency of femoral shaft fractures
(including AFFs) was investigated. The incidence of
femoral shaft fractureswas lowandnot significantly
higher amongst treated patients (Table 2b).
Medication persistence to acetylsalicylic acid did
not differ between current alendronate users and
nonalendronate users (Figure S1, P = 0.91).
The Cox assumption of proportional hazards was
fulfilled for all outcomes (Table S14).
Discussion
In the present study of patients aged 80 years and
older, we found robust and consistent associations
between alendronate use, regardless of treatment
definition, and reduced risk of hip fractures.
These results are consistent with a previous ran-
domized trial, reporting a maintained RRR of a
composite end-point of hip, spine and wrist
Table 2 (Continued )
Description No alendronate Alendronate P-value
Femoral shaft fractures
No. (%) 24 (0.3) 9 (0.5) 0.30
Per 100 000 person-years 206 287 0.40
Time to fracture, days – mean (SD) 474 (396) 484 (394) 0.95
Alendronate treatment (yes/no) HR (95% CI)
Crude 1.39 (0.65–2.99) 0.40
Adjusted for age, sex, weight, height 1.44 (0.67–3.10) 0.35
Multivariable adjustmenta 1.36 (0.57–3.23) 0.48
aMultivariable adjustment = age, sex, weight and height, and previous medication (glucocorticoids and calcium/vitamin
D), secondary osteoporosis, rheumatoid arthritis, alcohol-related diseases, Charlson comorbidity index, time since
fracture, previous vertebral fracture, previous hip fracture, previous hip replacement, number of previous fractures,
previous fall injury and osteoporosis diagnosis.
Table 3 Number of hip fracture events and censored cases during study period
Year 0–1 1–2 2–3 3–4 4–5 5–6 6–7
No alendronate
Number of patients at risk at the beginning of period 7844 4368 2273 880 178 26 2
Number of hip fractures 292 114 65 11 2 0 0
Censoreda 3184 1981 1328 691 150 24 2
Alendronate
Number of patients at risk at the beginning of period 1961 1191 639 267 65 13 2
Number of hip fractures 43 23 12 3 0 0 0
Censoreda 727 529 360 199 52 11 2
aDue to death, emigration or end of study (Dec 31st, 2014).
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fracture, with increasing age, although patients
were less than 80 years at inclusion [22]. There are
no available studies with adequate sample size and
power investigating the effect of alendronate on hip
fracture risk in patients older than 80 years [10].
Risedronate has shown a remarkable 83% risk
reduction in vertebral fracture in an old population
(n = 1392, aged 80–98, mean (SD) 83.0 (3.0)), but
the risk of nonvertebral fractures was not signifi-
cantly lower; however, unlike in our study, not all
participants had a prior fracture [23].
Screening women aged 65 years and older followed
by treatment with alendronate resulted in cost
savings and QALY increases if the yearly alen-
dronate cost is USD 200 or less [24]. The current
cost of alendronate is less than a third and our
study population is older indicating a highly
favourable cost-benefit perspective for alendronate
treatment amongst the oldest-old.
Treating older andoften frail patients could increase
the rate of known adverse events such as UGI
symptoms and possibly be harmful. We observed
indeed an increased risk ofmild UGI symptoms, but
the NNH for current users was 91, as compared to
the NNT of 26 for hip fracture, which in all could be
considered as a favourable risk-benefit ratio. As no
significant increased risk of peptic ulcers, femoral
shaft fracture or mortality was found, and the cases
of drug-induced osteonecrosis were too few to anal-
yse, our data indicate that alendronate treatment is
safe, also in very old patients. Despite the relatively
large sample size, the short follow-up timemay have
limited the ability to detect rare adverse events such
as atypical femur fractures, linked to long treatment
durations. However, a recent nested case control
study showed an acceptable balance of risk and
benefit even with long alendronate treatment [25].
We found that treatment was associated with a 12%
reduction in mortality, which is in line with a meta-
analysis of RCTs demonstrating a 10% risk reduc-
tion in mortality with antiresorptive treatment [26].
Deaths in relation to hip fracturewere less common,
although not significantly, in alendronate users
(Table S13).
To minimize the uncertainty of selection bias, we
used propensity score matching and obtained well-
balanced groups of treated and untreated patients.
Furthermore, we adjusted for Charlson morbidity
index, and other potential confounders in multi-
variable Cox models, which did not substantially
affect the observed associations. The lack of sig-
nificant differences in acetylsalicylic acid medica-
tion persistence between alendronate-treated
versus untreated patients indicates there was no
healthy adherer effect. Furthermore, investigating
concomitant medication in alendronate-treated
and untreated patients did not indicate that alen-
dronate users were healthier than nonusers.
Despite these performed measures to control for
possible bias, we cannot rule out that other selec-
tion factors for choosing which patients to treat
could exist, and as a result, the observed associ-
ations could have been affected by other differ-
ences in patient characteristics not controlled for
in this study.
The relatively high fallout from censored cases is a
consequence of the cohort being old (all patients
were 80 years or older – in order to study alen-
dronate in the oldest-old) with high mortality and
the relatively short follow-up time (mean
18 months), whilst some cases have up to 7 years
Fig. 3 Hip fracture risk with and without alendronate
amongst the oldest-old. Cox regression model, multivari-
able adjustment*. *multivariable adjustment = age, sex,
weight and height, and previous medication (glucocorti-
coids and calcium/vitamin D), secondary osteoporosis,
rheumatoid arthritis, alcohol-related diseases, Charlson
comorbidity index, time since fracture, previous vertebral
fracture, previous hip fracture, previous hip replacement,
number of previous fractures, previous fall injury and
osteoporosis diagnosis.
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of follow-up. As alendronate has a very long half-
time in the skeleton, (~10 years) not adjusting for
incident alendronate during a short follow-up time
is not likely to have a major impact on the observed
observation, especially as most patients in the
study had a short follow-up time.
In Sweden, supplementation treatment with cal-
cium and vitamin D is recommended for all
patients with active osteoporosis medication,
including alendronate. Therefore, it was not possi-
ble to study the effect of alendronate alone, as this
therapy should not be taken without calcium and
vitamin D. Patients taking only alendronate and
not calcium and vitamin D would neither be many,
nor representative. Instead, we adjusted for cal-
cium and vitamin D intake in the Cox models to
study the independent association between alen-
dronate and fracture risk. This adjustment did not
have any substantial effect of the observed obser-
vations.
It has been argued that pharmacological treatment
to prevent hip fracture is ineffective and that other
measures such as physical activity, cessation of
smoking and optimizing the diet should be
prioritized instead [27]. Although no adequately
powered randomized trial has been able to
show that any of these measures can prevent hip
fractures, there is available evidence supporting
interventions to prevent falls [28]. Nonpharmaco-
logical measures including fall prevention are
therefore currently recommended in addition to
pharmacological treatment in clinical guidelines
for treating osteoporosis [29, 30]. In the present
study, we observed an association between alen-
dronate treatment and reduced risk of hip fracture
in the subset of patients (n = 6935) who had
experienced a previous fall injury. Although this
association was similar in patients without a fall
injury, the association did not reach statistical
significance, which could be due to the relatively
small number of patients in that group (n = 2870).
Lack of a significant interaction between alen-
dronate treatment and prevalent fall injury
regarding the association with hip fracture indi-
cates a similar role of alendronate irrespective of
fall history.
A limitation of the present study is the lack of data
regarding bone densitometry and fracture trauma
type. However, there is evidence that trauma type
does not discriminate osteoporotic from nonosteo-
porotic fractures [31]. It should be acknowledged
that treatments with zoledronic acid have become
more widely used during recent years in Sweden
[32], and are rarely registered in the Drug Dispen-
sation Register as it is provided by hospital osteo-
porosis clinics. Therefore, it is likely that some of
the patients in our control group could have
received this treatment, which would then have
reduced the fracture risk in the control group,
resulting in attenuated associations between alen-
dronate and hip fracture risk seen in our popula-
tion. Furthermore, the proportion of patients with
an osteoporosis diagnosis was larger in the alen-
dronate treatment group than in the control group.
Acknowledging these sources of bias, the observed
relative risk reduction in our cohort of 34% for hip
fractures (compared to the 40% reduction reported
in RCTs) may be slightly underestimated [9]. Our
results emanate from a primarily Caucasian pop-
ulation and may not be generalizable to other
populations.
In conclusion, alendronate treatment was associ-
ated with reduced hip fracture risk in the
oldest-old. These results suggest that alendronate
treatment in the oldest-old is effective and safe,
and should be considered in older patients in
order to reduce the high fracture rates in this age
group.
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